FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1838596935> ?p ?o ?g. }

• W1838596935 endingPage "45" @default.
• W1838596935 startingPage "937" @default.
• W1838596935 abstract "The term secondary leukemia is usually employed to indicate both forms of acute myeloid leukemia (AML) evolving from previous myelodysplasia and forms of acute leukemia developing after exposure to environmental or therapeutic toxins or radiation (therapy related). Secondary leukemias account for 10-30% of all AML. The majority of secondary leukemias resulting from the use of cytotoxic drugs can be divided into two well defined groups depending on whether the patient has received 1) alkylating agents or 2) drugs binding to the enzyme DNA-topoisomerase II. Alkylating agents related leukemias are very similar to post MDS leukemias being characterized frequently by a preleukemic phase, tri-lineage dysplasia, frequent cytogenetic abnormalities involving chromosomes 5 and 7 and a poor prognosis. Secondary leukemias related to therapy with topoisomerase II inhibitors are not preceded by a preleukemic phase and show frequently balanced translocations involving chromosome 11q23. Among therapy-related leukemias, AML is generally a second neoplasm, thus a predisposition to malignancy, independently from previous chemotherapy, cannot be excluded. This review article examines the incidence of all secondary AMLs and the risk of therapy-related leukemia in relation to the different primary malignancies and treatments.The authors have been working in this field, both experimentally and at clinical level, contributing original papers for many years. In addition, the material examined in this review includes articles published in journals covered by MedLine, reviews in journals with high impact factor and recent reports presented at the Secondary Leukemia. An Update Symposium held in Rome in November 1998.The incidence of secondary leukemias is increasing because of aging of the population (MDS is more frequent in elderly people) and widespread and successful use of chemoradiotherapy in cancer patients. In the GIMEMA archive of adult acute leukemia (2,964 AML pts from June 1992 to June 1996) an antecedent hematologic disorder (AHD) and/or MDS was found in 8% of all patients (10% of 2,118 patients aged more than 45 years and in 4% of 848 patients aged less than 45). In this series of patients, 6% of all myeloid leukemias were therapy-related leukemia. Therapy-related leukemias are a major problem in patients treated for Hodgkin's disease, non-Hodgkin's lymphoma, myeloma, polycythemia, breast cancer, ovarian carcinoma, or testicular carcinoma. In the GIMEMA archive more than 50% of patients with secondary AML have breast cancer, NHL, and HD. Alkylating agents, nitrosureas and procarbazine appear to have the highest leukemogenic potential. Furthermore aggressive chemotherapy and radiotherapy followed or not by hematopoietic stem cell infusion will produce a more and more prolonged survival but also a greater incidence of secondary AML. Assessment of the risk of secondary leukemia should become part of any therapeutic plan for cancer patients. Avoidance of drugs with more leukemogenic potential will produce a marked reduction of secondary AML." @default.
• W1838596935 created "2016-06-24" @default.
• W1838596935 creator A5016603192 @default.
• W1838596935 creator A5023231352 @default.
• W1838596935 creator A5028315396 @default.
• W1838596935 creator A5077541772 @default.
• W1838596935 creator A5081247845 @default.
• W1838596935 date "1999-10-01" @default.
• W1838596935 modified "2023-09-30" @default.
• W1838596935 title "The incidence of secondary leukemias." @default.
• W1838596935 cites W1143126211 @default.
• W1838596935 cites W1446966563 @default.
• W1838596935 cites W161140084 @default.
• W1838596935 cites W1785638885 @default.
• W1838596935 cites W1833467461 @default.
• W1838596935 cites W1833833181 @default.
• W1838596935 cites W1843077828 @default.
• W1838596935 cites W1844816815 @default.
• W1838596935 cites W1873070501 @default.
• W1838596935 cites W1877303819 @default.
• W1838596935 cites W1882262018 @default.
• W1838596935 cites W1905906989 @default.
• W1838596935 cites W1921932494 @default.
• W1838596935 cites W1932077118 @default.
• W1838596935 cites W1937538988 @default.
• W1838596935 cites W1941328144 @default.
• W1838596935 cites W1941946666 @default.
• W1838596935 cites W1961339306 @default.
• W1838596935 cites W1963335440 @default.
• W1838596935 cites W1966444756 @default.
• W1838596935 cites W1968085043 @default.
• W1838596935 cites W1975829266 @default.
• W1838596935 cites W1978532753 @default.
• W1838596935 cites W198269578 @default.
• W1838596935 cites W1983781920 @default.
• W1838596935 cites W1985190619 @default.
• W1838596935 cites W1989108484 @default.
• W1838596935 cites W1998101819 @default.
• W1838596935 cites W2000852941 @default.
• W1838596935 cites W2005111613 @default.
• W1838596935 cites W2007532842 @default.
• W1838596935 cites W2013261471 @default.
• W1838596935 cites W2018476901 @default.
• W1838596935 cites W2027777838 @default.
• W1838596935 cites W2030319003 @default.
• W1838596935 cites W2031454576 @default.
• W1838596935 cites W2032801230 @default.
• W1838596935 cites W2033172039 @default.
• W1838596935 cites W2036021401 @default.
• W1838596935 cites W2037830358 @default.
• W1838596935 cites W2048517151 @default.
• W1838596935 cites W2050760756 @default.
• W1838596935 cites W2053399411 @default.
• W1838596935 cites W2059403857 @default.
• W1838596935 cites W2063965690 @default.
• W1838596935 cites W2069949935 @default.
• W1838596935 cites W2072552285 @default.
• W1838596935 cites W2072990071 @default.
• W1838596935 cites W2076244798 @default.
• W1838596935 cites W2081074855 @default.
• W1838596935 cites W2083912192 @default.
• W1838596935 cites W2084602921 @default.
• W1838596935 cites W2086855613 @default.
• W1838596935 cites W2094663887 @default.
• W1838596935 cites W2100482002 @default.
• W1838596935 cites W2105643967 @default.
• W1838596935 cites W2128153406 @default.
• W1838596935 cites W2140651954 @default.
• W1838596935 cites W2154177807 @default.
• W1838596935 cites W2156613346 @default.
• W1838596935 cites W2229863299 @default.
• W1838596935 cites W2236068781 @default.
• W1838596935 cites W2242925189 @default.
• W1838596935 cites W2245871225 @default.
• W1838596935 cites W2254790057 @default.
• W1838596935 cites W2263214337 @default.
• W1838596935 cites W2269139791 @default.
• W1838596935 cites W2300648760 @default.
• W1838596935 cites W2313420578 @default.
• W1838596935 cites W2320188351 @default.
• W1838596935 cites W2333611917 @default.
• W1838596935 cites W2338057729 @default.
• W1838596935 cites W2340198921 @default.
• W1838596935 cites W2341591060 @default.
• W1838596935 cites W2395585278 @default.
• W1838596935 cites W2396610512 @default.
• W1838596935 cites W2404651542 @default.
• W1838596935 cites W2410215670 @default.
• W1838596935 cites W2410413617 @default.
• W1838596935 cites W2440561267 @default.
• W1838596935 cites W2611745499 @default.
• W1838596935 cites W3149999723 @default.
• W1838596935 cites W3216969744 @default.
• W1838596935 cites W42721487 @default.
• W1838596935 cites W46453237 @default.
• W1838596935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10509043" @default.
• W1838596935 hasPublicationYear "1999" @default.
• W1838596935 type Work @default.

• next